Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
29.85
+0.14 (0.47%)
Sep 2, 2026, 4:00 PM EDT - Market closed
Arcus Biosciences Revenue
Arcus Biosciences had revenue of $41.00M in the quarter ending June 30, 2026, a decrease of -74.38%. This brings the company's revenue in the last twelve months to $117.00M, down -55.34% year-over-year. In the year 2025, Arcus Biosciences had annual revenue of $247.00M, down -4.26%.
Revenue (ttm)
$117.00M
Revenue Growth
-55.34%
P/S Ratio
32.49
Revenue / Employee
$194,676
Employees
601
Market Cap
3.80B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 247.00M | -11.00M | -4.26% |
| Dec 31, 2024 | 258.00M | 141.00M | 120.51% |
| Dec 31, 2023 | 117.00M | 5.00M | 4.46% |
| Dec 31, 2022 | 112.00M | -271.00M | -70.76% |
| Dec 31, 2021 | 383.00M | 305.00M | 391.03% |
| Dec 31, 2020 | 78.00M | 63.00M | 420.00% |
| Dec 31, 2019 | 15.00M | 6.65M | 79.58% |
| Dec 31, 2018 | 8.35M | 6.94M | 491.15% |
| Dec 31, 2017 | 1.41M | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| Telix Pharmaceuticals | 890.79M |
| Iovance Biotherapeutics | 324.97M |
| IDEAYA Biosciences | 234.13M |
| AbCellera Biologics | 66.17M |
| Tango Therapeutics | 53.81M |
| Relay Therapeutics | 10.35M |
| Denali Therapeutics | 3.60M |
RCUS News
- 7 days ago - Arcus Biosciences to Participate in Three Upcoming Investor Conferences - Business Wire
- 22 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 23 days ago - Arcus Biosciences price target raised to $23 from $22 at Morgan Stanley - TheFly
- 26 days ago - Arcus Biosciences price target raised to $42 from $34 at Goldman Sachs - TheFly
- 27 days ago - Arcus Biosciences price target raised to $43 from $41 at Wedbush - TheFly
- 27 days ago - Arcus Biosciences price target raised to $26 from $23 at Wells Fargo - TheFly
- 4 weeks ago - Arcus Biosciences reports Q2 EPS (72c), consensus (81c) - TheFly
- 4 weeks ago - Arcus Biosciences Earnings Call Transcript: Q2 2026 - Transcripts